Results 231 to 240 of about 1,553,588 (375)

Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors. [PDF]

Oncologist
Tsimberidou AM, Dayyani F, Sommerhalder D, Vandross AL, Pelster MS, Henry JT, Perez CA, Chakraborty A, Baysal MA, Chandhasin C, Dai Y, Tu S, King I, Perabo F.   +13 more
europepmc   +1 more source

The body fluids: Basic physiology and practical therapeutics [PDF]

, 1956
Louis M. Hellman
openalex   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

CNS Involvement by North American-Adult T-cell Leukemia/Lymphoma Is Associated With Discrete Dissemination Patterns and Molecular Profiles, Involving XPO1 E571 and KLF2/PI3KCD in Selected Cases. [PDF]

JCO Precis Oncol
Shah N, Suchanek M, Thakkar A, Patel RJ, Rahman S, Acuna-Villaorduna A, Shah U, Adrianzen Herrera D, Slasky S, Gritsman K, Goldfinger M, Shastri A, Mantzaris I, Kornblum N, Bachier-Rodriguez L, Feldman E, Cooper D, McNeill KA, Wang Y, Shi Y, Verma A, Ye BH, Janakiram M, Sica RA.   +23 more
europepmc   +1 more source

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

Molecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul, François Guillonneau, Odile Blanchet, Hamza Lasla, Audrey Rousseau, Catherine Guette, Alice Boissard, Cécile Henry, Morgan Dhondt, Pascal Jézéquel, Philippe Menei, Jean‐Michel Lemée   +11 more
wiley   +1 more source

Author's Reply to Gonçalves: "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review". [PDF]

BioDrugs
Lee CS.
europepmc   +1 more source

An essay on the antiquity of Hindoo medicine, including an introductory lecture to the course of materia medica and therapeutics, delivered at King's College

John Forbes Royle
openalex   +2 more sources

Veterinary materia medica and therapeutics

, 1901
Kenelm Winslow
openalex   +2 more sources

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial. [PDF]

ESMO Open
Melisi D, Macarulla T, De La Fouchardière C, Pazo Cid RA, Chandana SR, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Maxwell F, Zhang L, Benzaghou F, O'Reilly EM, Wainberg ZA.   +17 more
europepmc   +1 more source